Johnson & Johnson Reports 2010 Second-Quarter Results:

Sales of $15.3 Billion Increased 0.6% Versus 2009 Second-Quarter; EPS was $1.23 Excluding Special Items, 2010 Second-Quarter EPS was $1.21, an increase of 5.2%*

NEW BRUNSWICK, N.J., July 20 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE:JNJ) today announced sales of $15.3 billion for the second quarter of 2010, an increase of 0.6% as compared to the second quarter of 2009. Operational results increased 0.1% and the positive impact of currency was 0.5%. Domestic sales declined 2.8%, while international sales increased 4.1%, reflecting operational growth of 3.0% and a positive currency impact of 1.1%.
 

Net earnings and diluted earnings per share for the second quarter of 2010 were $3.4 billion and $1.23, respectively. Second-quarter 2010 net earnings included an after-tax gain of $67 million representing the net impact of litigation matters. Excluding this special item, net earnings for the current quarter were $3.4 billion and diluted earnings per share were $1.21, representing increases of 5.4% and 5.2%, respectively, as compared to the same period in 2009.*
 

The Company updated its earnings guidance for full-year 2010 to $4.65 - $4.75 per share, which excludes the impact of special items. The Company's guidance now reflects the impact of the voluntary recalls announced earlier this year of certain over-the-counter medicines and the suspension of manufacturing at the McNeil Consumer Healthcare facility in Fort Washington, Pa., as well as unfavorable changes in foreign currency exchange rates.
 

"Our second-quarter results include strong growth in a number of our recently launched products which contributed to solid earnings," said William C. Weldon, Chairman and Chief Executive Officer. "Remedial actions to address the product quality issues at McNeil Consumer Healthcare are ongoing and of high importance. At the same time, we continue to make significant investments in acquisitions, strategic partnerships and in advancing our pipeline, positioning us well for future growth."
 

Worldwide Consumer sales of $3.6 billion for the second quarter represented a decrease of 5.4% versus the prior year consisting of an operational decline of 6.5% and a positive impact from currency of 1.1%. Domestic sales decreased 14.3%; international sales increased 1.8%, which reflected an operational decline of 0.2% and a positive currency impact of 2.0%.
 

Positive contributors to operational results were NEUTROGENA®, international sales of Baby Care products and JOHNSON'S® adult skin products. These operational sales increases were more than offset by the impact of the previously announced recalls of certain over-the-counter medicines and the suspension of manufacturing at the McNeil Consumer Healthcare Fort Washington, Pa., facility as well as the economic situation in Venezuela.
 

Worldwide Pharmaceutical sales of $5.6 billion for the second quarter represented an increase of 1.0% versus the prior year with operational growth of 1.0% with no impact from currency. Domestic sales decreased 2.0%; international sales increased 5.0%, which reflected an operational increase of 4.9% and a positive currency impact of 0.1%.
 

Sales growth includes the strong performance of newly launched products including STELARA(TM) (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis; SIMPONI(TM) (golimumab), a biologic approved to treat adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis; and INVEGA® SUSTENNA(TM) (paliperidone palmitate) extended-release injectable suspension for the acute and maintenance treatment of schizophrenia in adults.
 

Several other products had strong operational growth including PREZISTA® (darunavir), a treatment for HIV; VELCADE® (bortezomib), a treatment for multiple myeloma; international sales of RISPERDAL® CONSTA® (risperidone) Long-Acting Treatment, an antipsychotic medication; and INTELENCE® (etravirine), a next generation non-nucleoside reverse transcriptase inhibitor for HIV.
 

Sales results of TOPAMAX® (topiramate), an antiepileptic and a treatment for migraine, and RISPERDAL® (risperidone), an antipsychotic medication, were negatively impacted by continued generic competition.
 

During the quarter, the Company acquired RespiVert Ltd., a privately held drug discovery company focused on developing small-molecule, inhaled therapies for the treatment of pulmonary diseases.
 

Additionally the Company signed an exclusive agreement with Diamyd Medical AB to develop and commercialize the GAD65 antigen-based diabetes therapy.
 

Worldwide Medical Devices and Diagnostics sales of $6.1 billion for the second quarter represented an increase of 4.1% versus the prior year consisting of an operational increase of 3.5% and a positive currency impact of 0.6%. Domestic sales increased 3.2%; international sales increased 5.0%, which reflected an operational increase of 3.9% and a positive currency impact of 1.1%.
 

Primary contributors to operational growth included Ethicon's surgical care products; Ethicon Endo-Surgery's minimally invasive and advanced sterilization products; Biosense Webster's electrophysiology business; and DePuy's orthopaedic joint reconstruction business. This growth was partially offset by lower sales in the Cordis franchise, reflecting continued competition in the drug-eluting stent market.
 

During the quarter, the Company received clearance from the United States Food and Drug Administration to market narafilcon B, the first and only silicone hydrogel daily disposable contact lens in the United States, which will be marketed under the name 1-DAY ACUVUE® TruEye(TM) Brand Contact Lenses.
 

In July, the Company entered into a definitive agreement to acquire Micrus Endovascular, a global developer and manufacturer of minimally invasive devices to address hemorrhagic and ischemic stroke. Also in July, Ethicon Endo-Surgery completed the divestiture of its Breast Care business to Devicor Medical Products, Inc.
 

About Johnson & Johnson
 

Caring for the world, one person at a time...inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 114,000 employees at more than 250 Johnson & Johnson companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.
 

* Net earnings and diluted earnings per share excluding special items, such as the net impact of litigation gains, are non-GAAP financial measures and should not be considered replacements for GAAP results. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measure can be found in the Investor Relations section of the Company's website at www.jnj.com.
 

NOTE TO INVESTORS
 

Johnson & Johnson will conduct a conference call with financial analysts to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the meeting for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com.
 

Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. These schedules include supplementary sales data, a condensed consolidated statement of earnings, and sales of key products/franchises. Additional information on Johnson & Johnson, including a pharmaceutical pipeline of selected compounds in late stage development and medical devices and diagnostics pipeline of selected products, can be found on the Company's website at www.jnj.com.
 

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Johnson & Johnson's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2010. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)
 


  Johnson & Johnson and Subsidiaries

  ----------------------------------

  Supplementary Sales Data


  (Unaudited;

   Dollars in

   Millions)                       SECOND QUARTER

  -----------                      --------------

                                                 Percent Change

                                                 --------------

                       2010   2009      Total         Operations Currency

                       ----   ----      -----         ---------- --------

  Sales to

   customers by

  segment of

   business


  Consumer

      U.S.           $1,463  1,708       (14.3)%     (14.3)           -

      International   2,184  2,146          1.8        (0.2)        2.0

      -------------   -----  -----          ---        ----         ---

                      3,647  3,854         (5.4)       (6.5)        1.1

                      =====  =====         ====        ====         ===


  Pharmaceutical

      U.S.            3,110  3,172         (2.0)       (2.0)          -

      International   2,443  2,326          5.0         4.9         0.1

      -------------   -----  -----          ---         ---         ---

                      5,553  5,498          1.0         1.0         0.0

                      =====  =====          ===         ===         ===


  Med Devices &

   Diagnostics

      U.S.            2,865  2,776          3.2         3.2           -

      International   3,265  3,111          5.0         3.9         1.1

      -------------   -----  -----          ---         ---         ---

                      6,130  5,887          4.1         3.5         0.6

                      =====  =====          ===         ===         ===


  U.S.                7,438  7,656         (2.8)       (2.8)          -

  International       7,892  7,583          4.1         3.0         1.1

  -------------       -----  -----          ---         ---         ---

  Worldwide         $15,330 15,239          0.6%        0.1         0.5

  =========         ======= ======          ===         ===         ===






  (Unaudited;

   Dollars in

   Millions)                        SIX MONTHS

  -----------                       ----------

                                                Percent Change

                                                --------------

                        2010   2009    Total         Operations Currency

                        ----   ----    -----         ---------- --------

  Sales to customers

   by

  segment of

   business


  Consumer

      U.S.            $3,023  3,434     (12.0)%     (12.0)           -

      International    4,390  4,131        6.3         0.6         5.7

      -------------    -----  -----        ---         ---         ---

                       7,413  7,565       (2.0)       (5.1)        3.1

                       =====  =====       ====        ====         ===


  Pharmaceutical

      U.S.             6,316  6,846       (7.7)       (7.7)          -

      International    4,875  4,432       10.0         5.7         4.3

      -------------    -----  -----       ----         ---         ---

                      11,191 11,278       (0.8)       (2.5)        1.7

                      ====== ======       ====        ====         ===


  Med Devices &

   Diagnostics

      U.S.             5,751  5,428        6.0         6.0           -

      International    6,606  5,994       10.2         5.6         4.6

      -------------    -----  -----       ----         ---         ---

                      12,357 11,422        8.2         5.8         2.4

                      ====== ======        ===         ===         ===


  U.S.                15,090 15,708       (3.9)       (3.9)          -

  International       15,871 14,557        9.0         4.2         4.8

  -------------       ------ ------        ---         ---         ---

  Worldwide          $30,961 30,265        2.3%        0.0         2.3

  =========          ======= ======        ===         ===         ===




  Johnson & Johnson and Subsidiaries

  ----------------------------------

  Supplementary Sales Data


  (Unaudited; Dollars in

   Millions)                            SECOND QUARTER

  ----------------------                --------------

                                                     Percent Change

                                                     --------------

                            2010   2009    Total        Operations  Currency

                            ----   ----    -----        ----------  --------

  Sales to customers by

  geographic area


  U.S.                    $7,438  7,656     (2.8)%       (2.8)           -

  ----                    ------  -----     -----        ----          ---


  Europe                   3,832  3,972      (3.5)        1.3         (4.8)

  Western Hemisphere

   excluding U.S.          1,375  1,215      13.2         2.6         10.6

  Asia-Pacific, Africa     2,685  2,396      12.1         6.1          6.0

  International            7,892  7,583       4.1         3.0          1.1

  -------------            -----  -----       ---         ---          ---


  Worldwide              $15,330 15,239       0.6%        0.1          0.5

  =========              ======= ======       ===         ===          ===






  (Unaudited; Dollars in

   Millions)                            SIX MONTHS

  ----------------------                ----------

                                                   Percent Change

                                                   --------------

                            2010   2009   Total        Operations Currency

                            ----   ----   -----        ---------- --------

  Sales to customers by

  geographic area


  U.S.                   $15,090 15,708    (3.9)%       (3.9)          -

  ----                   ------- ------    -----        ----         ---


  Europe                   7,934  7,643      3.8         2.9         0.9

  Western Hemisphere

   excluding U.S.          2,655  2,277     16.6         3.1        13.5

  Asia-Pacific, Africa     5,282  4,637     13.9         6.9         7.0


  International           15,871 14,557      9.0         4.2         4.8

  -------------           ------ ------      ---         ---         ---


  Worldwide              $30,961 30,265      2.3%        0.0         2.3

  =========              ======= ======      ===         ===         ===








  Johnson & Johnson and Subsidiaries

  ----------------------------------

  Condensed Consolidated Statement of Earnings



  (Unaudited; in Millions 

   Except Per Share Figures)                  SECOND QUARTER

  --------------------------                  --------------



                                   2010              2009     

                            ---------------- ----------------   Percent

                                    Percent           Percent  Increase

                             Amount to Sales  Amount to Sales (Decrease)

  ---------------------------------------------------------------------

  Sales to customers        $15,330    100.0 $15,239   100.0        0.6

  ------------------        -------    ----- -------   -----        ---

  Cost of products sold       4,630     30.2   4,450    29.2        4.0

  Selling, marketing and

   administrative expenses    4,756     31.0   4,797    31.5       (0.9)

  Research expense            1,648     10.8   1,638    10.7        0.6

  Interest (income)expense,

   net                           58      0.4      85     0.6

  Other (income)expense,

   net                           18      0.1       6       -

  ----------------------        ---      ---     ---     ---

  Earnings before provision

   for taxes on income        4,220     27.5   4,263    28.0       (1.0)

  Provision for taxes on

   income                       771      5.0   1,055     6.9      (26.9)

                                         ---             ---      -----

  Net earnings               $3,449     22.5  $3,208    21.1        7.5

  ============               ======     ====  ======    ====        ===


  Net earnings per share

   (Diluted)                  $1.23            $1.15                7.0


  Average shares

   outstanding  (Diluted)   2,796.0          2,782.0


  Effective tax rate           18.3%            24.7%


  Adjusted earnings before

   provision for taxes and

   net earnings

    Earnings before

     provision for

     taxes on income         $4,377 (1) 28.6  $4,263    28.0        2.7

    Net earnings             $3,382 (1) 22.1  $3,208    21.1        5.4

    Net earnings per

     share (Diluted)          $1.21 (1)        $1.15                5.2

    Effective tax

     rate                      22.7%            24.7%

    -------------              ----             ----


  (1) The difference between as reported and as adjusted earnings is

  the exclusion of second quarter net litigation.  The impact of

  second quarter net litigation is $157 million expense on earnings

  before provision for taxes on income, $67 million income on net

  earnings and $0.02 per share on net earnings per share (diluted).








  Johnson & Johnson and Subsidiaries

  ----------------------------------

  Condensed Consolidated Statement of Earnings


  (Unaudited; in Millions Except

   Per Share Figures)                          SIX MONTHS

  -------------------                          ----------



                                2010              2009     

                         ----------------  ----------------     Percent

                                  Percent           Percent    Increase

                          Amount to Sales   Amount to Sales   (Decrease)

  ---------------------------------------------------------------------

  Sales to customers     $30,961    100.0  $30,265    100.0         2.3

  ------------------     -------    -----  -------    -----         ---

  Cost of products sold    9,158     29.6    8,701     28.7         5.3

  Selling, marketing and

   administrative

   expenses                9,535     30.8    9,405     31.1         1.4

  Research expense         3,205     10.4    3,156     10.4         1.6

  Interest

   (income)expense, net      139      0.4      166      0.6

  Other (income)expense,

   net                   (1,576)     (5.1)     (69)    (0.2)

  ----------------------  ------     ----      ---     ----

  Earnings before

   provision for taxes

   on income              10,500     33.9    8,906     29.4        17.9

  Provision for taxes on

   income                  2,525      8.1    2,191      7.2        15.2

                                      ---               ---        ----

  Net earnings            $7,975     25.8   $6,715     22.2        18.8

  ============            ======     ====   ======     ====        ====


  Net earnings per share

    (Diluted)              $2.85             $2.41                 18.3


  Average shares

   outstanding

   (Diluted)             2,796.1           2,785.5


  Effective tax rate        24.0%             24.6%



  Adjusted earnings before 

   provision for taxes and

    net earnings

     Earnings before

      provision for taxes

      on income           $9,160 (1) 29.6   $8,906     29.4         2.9

     Net earnings         $6,998 (1) 22.6   $6,715     22.2         4.2

     Net earnings per 

      share (Diluted)      $2.50 (1)         $2.41                  3.7

     Effective tax rate     23.6%             24.6%

     ------------------     ----              ----



  (1) The difference between as reported earnings and as adjusted earnings

      before provision for taxes on income, net earnings and net earnings

      per share (diluted) is the exclusion of income from net litigation 

      of $1,340 million, $977 million and $0.35 per share, respectively.




   REPORTED SALES vs. PRIOR PERIOD ($MM)

   -------------------------------------


                                      SECOND QUARTER

                                      --------------

                                                  % Change

                                                  --------

                                                  Operational

                          2010   2009  Reported         (1)     Currency

                          ----   ----  --------   ------------  --------

  CONSUMER SEGMENT (2)

  --------------------

  SKIN CARE

  ---------

  US                       422    411       2.7%           2.7%        -

  Intl                     421    422      -0.2%          -0.5%      0.3%

  WW                       843    833       1.2%           1.1%      0.1%

  BABY CARE

  ---------

  US                        99    104      -4.8%          -4.8%        -

  Intl                     438    404       8.4%           4.9%      3.5%

  WW                       537    508       5.7%           2.9%      2.8%

  ORAL CARE

  ---------

  US                       148    174     -14.9%         -14.9%        -

  Intl                     224    212       5.7%           1.8%      3.9%

  WW                       372    386      -3.6%          -5.8%      2.2%

  OTC/NUTRITIONALS

  ----------------

  US                       492    679     -27.5%         -27.5%        -

  Intl                     649    631       2.9%           1.9%      1.0%

  WW                     1,141  1,310     -12.9%         -13.4%      0.5%

  WOMEN'S HEALTH

  --------------

  US                       137    152      -9.9%          -9.9%        -

  Intl                     329    329       0.0%          -2.1%      2.1%

  WW                       466    481      -3.1%          -4.5%      1.4%

  WOUND CARE / OTHER

  ------------------

  US                       165    188     -12.2%         -12.2%        -

  Intl                     123    148     -16.9%         -20.3%      3.4%

  WW                       288    336     -14.3%         -15.8%      1.5%

  TOTAL CONSUMER

  --------------

  US                     1,463  1,708     -14.3%         -14.3%        -

  Intl                   2,184  2,146       1.8%          -0.2%      2.0%

  WW                     3,647  3,854      -5.4%          -6.5%      1.1%

                         -----  -----      ----           ----       ---



  * See footnotes below



  PHARMACEUTICAL SEGMENT

   (2) (6)

  ----------------------

  ACIPHEX/PARIET

  --------------

  US                       121    128      -5.5%          -5.5%        -

  Intl                     133    132       0.8%           2.1%     -1.3%

  WW                       254    260      -2.3%          -1.6%     -0.7%

  CONCERTA

  --------

  US                       223    233      -4.3%          -4.3%        -

  Intl                     100     84      19.0%          16.3%      2.7%

  WW                       323    317       1.9%           1.2%      0.7%

  DURAGESIC/FENTANYL

   TRANSDERMAL

  ------------------

  US                        37     50     -26.0%         -26.0%        -

  Intl                     147    168     -12.5%         -12.6%      0.1%

  WW                       184    218     -15.6%         -15.7%      0.1%

  LEVAQUIN/FLOXIN

  ---------------

  US                       289    343     -15.7%         -15.7%        -

  Intl                      11     19     -42.1%         -44.8%      2.7%

  WW                       300    362     -17.1%         -17.2%      0.1%

  PREZISTA

  --------

  US                        99     65      52.3%          52.3%        -

  Intl                     105     75      40.0%          42.1%     -2.1%

  WW                       204    140      45.7%          46.8%     -1.1%

  PROCRIT/EPREX

  -------------

  US                       306    330      -7.3%          -7.3%        -

  Intl                     220    247     -10.9%          -9.3%     -1.6%

  WW                       526    577      -8.8%          -8.1%     -0.7%

  REMICADE

  --------

  US                       783    771       1.6%           1.6%        -

  US Exports (3)           341    327       4.3%           4.3%        -

  Intl                       6      4      50.0%          50.0%        -

  WW                     1,130  1,102       2.5%           2.5%        -

  RISPERDAL/RISPERIDONE

  ---------------------

  US                       (17)    70    -124.3%        -124.3%        -

  Intl                     134    169     -20.7%         -22.1%      1.4%

  WW                       117    239     -51.0%         -52.0%      1.0%

  RISPERDAL CONSTA

  ----------------

  US                       115    131     -12.2%         -12.2%        -

  Intl                     240    217      10.6%          12.8%     -2.2%

  WW                       355    348       2.0%           3.4%     -1.4%

  TOPAMAX

  -------

  US                        59     75     -21.3%         -21.3%        -

  Intl                      83    107     -22.4%         -21.4%     -1.0%

  WW                       142    182     -22.0%         -21.4%     -0.6%

  VELCADE

  -------

  US                         -      -         -              -         -

  Intl                     286    229      24.9%          25.1%     -0.2%

  WW                       286    229      24.9%          25.1%     -0.2%

  OTHER

  -----

  US                       754    649      16.2%          16.2%        -

  Intl                     978    875      11.8%          10.3%      1.5%

  WW                     1,732  1,524      13.6%          12.8%      0.8%

  TOTAL PHARMACEUTICAL

  --------------------

  US                     3,110  3,172      -2.0%          -2.0%        -

  Intl                   2,443  2,326       5.0%           4.9%      0.1%

  WW                     5,553  5,498       1.0%           1.0%      0.0%

                         -----  -----       ---            ---       ---

  MAJOR NEW PHARM

   PRODUCTS (4)

  ---------------

  INVEGA

  ------

  US                        68     67       1.5%           1.5%        -

  Intl                      34     32       6.3%           8.3%     -2.0%

  WW                       102     99       3.0%           3.6%     -0.6%

                           ---    ---       ---            ---      ----


  * See footnotes below

  MEDICAL DEVICES AND

   DIAGNOSTICS   (2)

  -------------------

  CORDIS (5)

  ----------

  US                       265    252       5.2%           5.2%        -

  Intl                     390    422      -7.6%          -8.6%      1.0%

  WW                       655    674      -2.8%          -3.4%      0.6%

  DEPUY

  -----

  US                       776    762       1.8%           1.8%        -

  Intl                     599    561       6.8%           6.0%      0.8%

  WW                     1,375  1,323       3.9%           3.5%      0.4%

  DIABETES CARE

  -------------

  US                       313    306       2.3%           2.3%        -

  Intl                     303    304      -0.3%           1.1%     -1.4%

  WW                       616    610       1.0%           1.7%     -0.7%

  ETHICON

  -------

  US                       509    452      12.6%          12.6%        -

  Intl                     623    589       5.8%           5.0%      0.8%

  WW                     1,132  1,041       8.7%           8.2%      0.5%

  ETHICON ENDO-SURGERY

  --------------------

  US                       507    489       3.7%           3.7%        -

  Intl                     689    626      10.1%           8.8%      1.3%

  WW                     1,196  1,115       7.3%           6.6%      0.7%

  ORTHO-CLINICAL

   DIAGNOSTICS

  --------------

  US                       264    284      -7.0%          -7.0%        -

  Intl                     230    210       9.5%           8.4%      1.1%

  WW                       494    494       0.0%          -0.5%      0.5%

  VISION CARE

  -----------

  US                       232    231       0.4%           0.4%        -

  Intl                     430    399       7.8%           3.9%      3.9%

  WW                       662    630       5.1%           2.6%      2.5%

  TOTAL MEDICAL DEVICES

   AND DIAGNOSTICS

  ---------------------

  US                     2,865  2,776       3.2%           3.2%        -

  Intl                   3,265  3,111       5.0%           3.9%      1.1%

  WW                     6,130  5,887       4.1%           3.5%      0.6%

                         -----  -----       ---            ---       ---






                                         SIX MONTHS

                                         ----------

                                                    % Change

                                                    --------

                                                  Operational

                          2010    2009 Reported         (1)     Currency

                          ----    ---- --------   ------------  --------

  CONSUMER SEGMENT (2)

  --------------------

  SKIN CARE

  ---------

  US                       874     834      4.8%           4.8%        -

  Intl                     889     841      5.7%           0.9%      4.8%

  WW                     1,763   1,675      5.3%           2.9%      2.4%

  BABY CARE

  ---------

  US                       202     206     -1.9%          -1.9%        -

  Intl                     864     791      9.2%           3.1%      6.1%

  WW                     1,066     997      6.9%           2.1%      4.8%

  ORAL CARE

  ---------

  US                       322     362    -11.0%         -11.0%        -

  Intl                     431     389     10.8%           3.3%      7.5%

  WW                       753     751      0.3%          -3.6%      3.9%

  OTC/NUTRITIONALS

  ----------------

  US                     1,034   1,405    -26.4%         -26.4%        -

  Intl                   1,314   1,253      4.9%          -0.5%      5.4%

  WW                     2,348   2,658    -11.7%         -14.3%      2.6%

  WOMEN'S HEALTH

  --------------

  US                       283     301     -6.0%          -6.0%        -

  Intl                     652     603      8.1%           2.4%      5.7%

  WW                       935     904      3.4%          -0.4%      3.8%

  WOUND CARE / OTHER

  ------------------

  US                       308     326     -5.5%          -5.5%        -

  Intl                     240     254     -5.5%         -11.4%      5.9%

  WW                       548     580     -5.5%          -8.1%      2.6%

  TOTAL CONSUMER

  --------------

  US                     3,023   3,434    -12.0%         -12.0%        -

  Intl                   4,390   4,131      6.3%           0.6%      5.7%

  WW                     7,413   7,565     -2.0%          -5.1%      3.1%

                         -----   -----     ----           ----       ---



  * See footnotes below



  PHARMACEUTICAL

   SEGMENT  (2) (6)

  -----------------

  ACIPHEX/PARIET

  --------------

  US                       240     266     -9.8%          -9.8%        -

  Intl                     274     257      6.6%           2.7%      3.9%

  WW                       514     523     -1.7%          -3.6%      1.9%

  CONCERTA

  --------

  US                       454     502     -9.6%          -9.6%        -

  Intl                     198     159     24.5%          16.7%      7.8%

  WW                       652     661     -1.4%          -3.3%      1.9%

  DURAGESIC/FENTANYL

   TRANSDERMAL

  ------------------

  US                        75     125    -40.0%         -40.0%        -

  Intl                     293     324     -9.6%         -13.1%      3.5%

  WW                       368     449    -18.0%         -20.5%      2.5%

  LEVAQUIN/FLOXIN

  ---------------

  US                       652     751    -13.2%         -13.2%        -

  Intl                      19      36    -47.2%         -50.2%      3.0%

  WW                       671     787    -14.7%         -14.8%      0.1%

  PREZISTA

  --------

  US                       188     137     37.2%          37.2%        -

  Intl                     203     125     62.4%          57.3%      5.1%

  WW                       391     262     49.2%          46.8%      2.4%

  PROCRIT/EPREX

  -------------

  US                       596     651     -8.4%          -8.4%        -

  Intl                     453     476     -4.8%          -7.8%      3.0%

  WW                     1,049   1,127     -6.9%          -8.2%      1.3%

  REMICADE

  --------

  US                     1,563   1,508      3.6%           3.6%        -

  US Exports (3)           741     613     20.9%          20.9%        -

  Intl                      12       9     33.3%          33.2%      0.1%

  WW                     2,316   2,130      8.7%           8.7%        -

  RISPERDAL/RISPERIDONE

  ---------------------

  US                       (12)    188   -106.4%        -106.4%        -

  Intl                     267     326    -18.1%         -21.2%      3.1%

  WW                       255     514    -50.4%         -52.4%      2.0%

  RISPERDAL CONSTA

  ----------------

  US                       232     257     -9.7%          -9.7%        -

  Intl                     502     416     20.7%          16.9%      3.8%

  WW                       734     673      9.1%           6.8%      2.3%

  TOPAMAX

  -------

  US                       116     570    -79.6%         -79.6%        -

  Intl                     174     214    -18.7%         -21.6%      2.9%

  WW                       290     784    -63.0%         -63.8%      0.8%

  VELCADE

  -------

  US                         -       -      0.0%           0.0%        -

  Intl                     547     421     29.9%          25.8%      4.1%

  WW                       547     421     29.9%          25.8%      4.1%

  OTHER

  -----

  US                     1,471   1,278     15.1%          15.1%        -

  Intl                   1,933   1,669     15.8%          10.5%      5.3%

  WW                     3,404   2,947     15.5%          12.5%      3.0%

  TOTAL PHARMACEUTICAL

  --------------------

  US                     6,316   6,846     -7.7%          -7.7%        -

  Intl                   4,875   4,432     10.0%           5.7%      4.3%

  WW                    11,191  11,278     -0.8%          -2.5%      1.7%

                        ------  ------     ----           ----       ---

  MAJOR NEW PHARM

   PRODUCTS (4)

  ---------------

  INVEGA

  ------

  US                       137     133      3.0%           3.0%        -

  Intl                      73      57     28.1%          23.8%      4.3%

  WW                       210     190     10.5%           9.2%      1.3%

                           ---     ---     ----            ---       ---


  * See footnotes below

  MEDICAL DEVICES AND

   DIAGNOSTICS   (2)

  -------------------

  CORDIS (5)

  ----------

  US                       516     498      3.6%           3.6%        -

  Intl                     811     844     -3.9%          -7.4%      3.5%

  WW                     1,327   1,342     -1.1%          -3.3%      2.2%

  DEPUY

  -----

  US                     1,590   1,528      4.1%           4.1%        -

  Intl                   1,239   1,087     14.0%           8.5%      5.5%

  WW                     2,829   2,615      8.2%           5.9%      2.3%

  DIABETES CARE

  -------------

  US                       603     576      4.7%           4.7%        -

  Intl                     610     575      6.1%           3.2%      2.9%

  WW                     1,213   1,151      5.4%           4.0%      1.4%

  ETHICON

  -------

  US                     1,019     857     18.9%          18.9%        -

  Intl                   1,260   1,137     10.8%           6.1%      4.7%

  WW                     2,279   1,994     14.3%          11.6%      2.7%

  ETHICON ENDO-SURGERY

  --------------------

  US                       990     943      5.0%           5.0%        -

  Intl                   1,374   1,187     15.8%          10.7%      5.1%

  WW                     2,364   2,130     11.0%           8.2%      2.8%

  ORTHO-CLINICAL

   DIAGNOSTICS

  --------------

  US                       552     561     -1.6%          -1.6%        -

  Intl                     467     400     16.8%          12.2%      4.6%

  WW                     1,019     961      6.0%           4.1%      1.9%

  VISION CARE

  -----------

  US                       481     465      3.4%           3.4%        -

  Intl                     845     764     10.6%           5.4%      5.2%

  WW                     1,326   1,229      7.9%           4.6%      3.3%

  TOTAL MEDICAL DEVICES

   AND DIAGNOSTICS

  ---------------------

  US                     5,751   5,428      6.0%           6.0%        -

  Intl                   6,606   5,994     10.2%           5.6%      4.6%

  WW                    12,357  11,422      8.2%           5.8%      2.4%

                        ------  ------      ---            ---       ---


  (1) Operational growth excludes the effect of currency

  (2) Select areas (unaudited)

  (3) Reported in U.S. sales

  (4) Included in Other

  (5) Includes sales of Drug-Eluting Stents for Q2 2010 of $59, $108

  and $167MM Domestic, International and Worldwide respectively

       Includes sales of Drug-Eluting Stents for Q2 2009 of $69, $165 and

       $234MM Domestic, International and Worldwide respectively

       Includes sales of Drug-Eluting Stents for June YTD 2010 of $119,

       $238 and $357MM Domestic, International and Worldwide respectively

       Includes sales of Drug-Eluting Stents for June YTD 2009 of $136,

       $349 and $485MM Domestic, International and Worldwide respectively

  (6) Conforms to current presentation

Source: Johnson & Johnson

CONTACT: Press, Jeffrey J. Leebaw, +1-732-524-3350, +1-732-642-6608 (M),
or Bill Price, +1-732-524-6623, +1-732-668-3735 (M); or Investors, Louise
Mehrotra, +1-732-524-6491, Stan Panasewicz, +1-732-524-2524, Lesley Fishman,
+1-732-524-3922, or Tina Pinto, +1-732-524-2034, all of Johnson & Johnson
 

Web Site: http://www.jnj.com/
 

Posted: July 2010


View comments

Hide
(web4)